Why Some Patients Report Mood Changes on GLP-1 Therapy Semaglutide works by stimulating GLP-1 receptors throughout the body and brain
Risk groups More often seen in the elderly, alcoholics, the homeless, or patients with chronic illnesses such as cancer or chronic renal failure
In a rat model of MCAO-induced stroke, neurogenesis was increased by semaglutide treatment, as evidenced by significantly increased levels of neurogenesis-specific biomarkers including nestin (intermediate filament protein that is a known marker of neuronal progenitor cells), doublecortin (microtubule-associated protein considered to be a reliable marker of neurogenesis), stromal cell-derived factor-1 (SDF-1) (chemokine promoting endogenous regeneration in the ischemic brain), and its receptor CXCR4
Quality Certifications : Seek products that have undergone third-party testing for potency and purity
Cacciatori V, Zoppini G, Bellavere F, Rigolon R, Thomaseth K, Pichiri I, et al